Garnon, J.
Van Strijen, M. J.
Nielsen, T. K.
King, A. J.
Montauban Van Swijndregt, A. D.
Cazzato, R. L.
Auloge, P.
Rousseau, C.
Dalili, D.
Keeley Jr, F. X.
Lagerveld, B. W.
Breen, D. J.
Article History
Received: 13 November 2018
Revised: 5 January 2019
Accepted: 20 March 2019
First Online: 15 April 2019
Compliance with ethical standards
:
: The scientific guarantor of this publication is Julien Garnon—University Hospital of Strasbourg.
: Dr. Garnon is a proctor for BTG Galil and received fees for oral presentation for Medtronic and Canon. Dr. Van Strijen, Lagerweld and Breen are proctors for BTG Galil. All other authors have no conflict of interest.
: Dr. Rousseau has significant statistical expertise.
: Written informed consent was obtained from all subjects (patients) in this study.
: Institutional Review Board approval was not required because of the retrospective design of the study.
: Some study subjects or cohorts have been previously reported in:• Buy X, Lang H, Garnon J, Sauleau E, Roy C, Gangi A. Percutaneous renal cryoablation: prospective experience treating 120 consecutive tumors. AJR Am J Roentgenol. 2013 Dec;201(6):1353–61. ExternalRef removed.• Breen DJ, Bryant TJ, Abbas A, Shepherd B, McGill N, Anderson JA, Lockyer RC,Hayes MC, George SL. Percutaneous cryoablation of renal tumours: outcomes from 171 tumours in 147 patients. BJU Int. 2013 Oct;112(6):758–65. ExternalRef removed.
: • retrospective• observational• multicentre study